NCT06297161
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML). Not Available Not Available not_yet_recruiting NCT03205267
Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients treatment 2 unknown_status NCT02730299
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS treatment 3 active_not_recruiting NCT01720264
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant treatment 2 completed NCT00179764
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) No drug interventions treatment Not Available completed NCT02736721
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) treatment 3 completed NCT02231853
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections No drug interventions prevention 1 terminated NCT01768845
Unrelated Umbilical Cord Blood (UBC)Transplantation No drug interventions treatment Not Available completed NCT01351545
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) No drug interventions Not Available Not Available recruiting NCT00471497
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) treatment 3 completed NCT01885897
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT treatment 1 / 2 completed NCT00111683
MK0457 in Patients With Leukemia (0457-003) No drug interventions treatment 1 completed NCT03128411
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia treatment 2 completed NCT02117115
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation screening 0 completed NCT04808115
IIT PH1 KDS-1001 in Patients With CML No drug interventions treatment 1 not_yet_recruiting NCT00672152
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation No drug interventions treatment 1 terminated NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders No drug interventions treatment Not Available recruiting NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies treatment 1 / 2 completed NCT01517035
Improving Blood Stem Cell Collection and Transplant Procedures No drug interventions treatment 1 / 2 completed NCT03885830
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients Not Available Not Available completed NCT02259348
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation treatment 2 terminated NCT01663766
Phase I Study of Milatuzumab for Graft Versus Host Disease treatment 1 terminated NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs treatment 2 terminated NCT01735955
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study treatment 4 completed NCT01050764
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells treatment 1 / 2 terminated NCT01503502
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia treatment 2 unknown_status NCT00619879
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies No drug interventions treatment 3 unknown_status NCT00569179
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies No drug interventions treatment 1 terminated NCT05884333
Cord Blood Transplant in Adults With Blood Cancers No drug interventions treatment 2 recruiting NCT00038597
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) treatment 2 completed NCT00467961
Stem Cell Transplantation for Patients With Cancers of the Blood No drug interventions treatment 2 completed NCT02226861
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation prevention 1 completed NCT02161978
Vascular Dysfunction and Antiangiogenic Therapy No drug interventions Not Available Not Available completed NCT00862719
Sitagliptin Umbilical Cord Blood Transplant Study treatment 2 completed NCT03959241
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) prevention 3 completed NCT05092048
A Study for PRO of CML in Real Word No drug interventions Not Available Not Available unknown_status NCT03421626
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML) No drug interventions Not Available Not Available completed NCT04795427
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors treatment 2 active_not_recruiting NCT01243489
Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation No drug interventions other 4 completed NCT04518644
Nilotinib, for Patients With CML-CP or CML-AP Not Available Not Available no_longer_available NCT00129740
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) treatment 2 completed NCT05640804
A Bioequivalence Study of Dasatinib Tablet treatment 1 completed NCT01413568
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies No drug interventions treatment 1 / 2 completed NCT00923910
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood treatment 1 / 2 completed NCT00185523
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) No drug interventions Not Available Not Available terminated NCT00718263
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase) treatment 3 active_not_recruiting NCT01784068
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients other 2 active_not_recruiting NCT04877522
Asciminib Roll-over Study treatment 4 recruiting NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available active_not_recruiting NCT00159003
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel No drug interventions Not Available Not Available completed NCT00041990
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) treatment 2 completed NCT06301321
The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia Patients No drug interventions Not Available Not Available recruiting NCT00047502
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia treatment 1 completed NCT01390402
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG treatment 2 completed NCT03106779
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs treatment 3 active_not_recruiting NCT01338987
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation treatment 2 completed NCT04191187
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT00990587
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy treatment 1 completed NCT00144677
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation prevention 2 completed NCT00760877
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) treatment 3 completed NCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies treatment 1 completed NCT00101647
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia treatment 2 completed NCT01011998
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) treatment 2 withdrawn NCT01611298
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR prevention Not Available completed NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases treatment 2 recruiting NCT02765997
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies No drug interventions treatment 2 withdrawn NCT02709083
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia treatment 2 terminated NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match treatment 2 terminated NCT00579111
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) treatment 1 / 2 terminated NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSC treatment 0 completed NCT02081378
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL treatment 1 completed NCT06088888
TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia No drug interventions treatment 1 recruiting NCT01130688
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. treatment 1 terminated NCT00109707
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies treatment 1 / 2 completed NCT00852709
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias treatment 1 terminated NCT05088356
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft treatment 1 recruiting NCT01149915
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias treatment 1 completed NCT01484015
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia treatment 1 completed NCT00346632
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia No drug interventions treatment 1 terminated NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer treatment 2 completed NCT00038870
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes No drug interventions treatment Not Available withdrawn NCT00811070
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias treatment 2 completed NCT00309842
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases treatment 2 completed NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT00171899
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) treatment 4 completed NCT00500006
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) treatment 1 terminated NCT02047149
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia treatment 1 terminated NCT00719836
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies treatment 1 / 2 completed NCT00079313
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia treatment 2 completed NCT00038818
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation No drug interventions treatment Not Available terminated NCT01030718
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL treatment 1 / 2 completed NCT00980018
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment treatment 4 completed NCT04888741
Methods of T Cell Depletion Trial (MoTD) prevention 2 recruiting NCT00954941
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis treatment 2 completed NCT00802841
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib treatment 3 completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT01634217
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation No drug interventions treatment 1 completed NCT01397734
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) treatment 1 terminated NCT00378534
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants treatment 2 completed NCT02661035
Allo HSCT Using RIC for Hematological Diseases treatment 2 completed NCT01364363
Unrelated Donor Stem Cell Transplantation No drug interventions treatment Not Available completed NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen No drug interventions Not Available Not Available recruiting NCT02145039
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases treatment Not Available terminated NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT01755325
Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ treatment 3 suspended NCT00626626
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation treatment 1 / 2 terminated NCT04282174
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies treatment 2 withdrawn NCT03314974
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders No drug interventions treatment 2 recruiting NCT00088231
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP treatment 1 / 2 completed NCT01110473
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies treatment 1 completed NCT01207076
AHN-12 Biodistribution in Advanced Leukemia No drug interventions treatment 1 terminated NCT00661180
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec treatment 2 completed NCT00709592
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT treatment 2 completed NCT02511340
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients treatment 2 unknown_status NCT03578367
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treatment 2 active_not_recruiting NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep treatment 2 active_not_recruiting NCT02146846
Population Pharmacokinetics of Imatinib in CML Patients in Iran Not Available Not Available terminated NCT00866346
PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation No drug interventions treatment 1 withdrawn NCT01366612
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation treatment 3 terminated NCT00493181
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients treatment 2 completed NCT00270881
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies treatment 1 / 2 completed NCT00368355
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts treatment 2 completed NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHD treatment Not Available terminated NCT01513603
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia treatment 2 unknown_status NCT00042003
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) treatment 2 completed NCT01494103
Administration of Donor T Cells With the Caspase-9 Suicide Gene treatment 1 active_not_recruiting NCT04014764
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy No drug interventions Not Available Not Available completed NCT02338479
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies No drug interventions Not Available Not Available active_not_recruiting NCT00674479
INCB018424 in Patients With Advanced Hematologic Malignancies treatment 2 completed NCT04948333
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP. treatment 3 active_not_recruiting NCT00098033
Investigation of Clofarabine in Acute Leukemias treatment 2 completed NCT01003054
Autologous Transplantation for Chronic Myelogenous Leukemia treatment 2 completed NCT03547154
Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) treatment 2 / 3 terminated NCT00337454
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan treatment 1 / 2 completed NCT01274351
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) treatment 2 completed NCT02743351
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies No drug interventions prevention 1 / 2 completed NCT02592447
Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention No drug interventions supportive_care Not Available completed NCT01499147
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies treatment Not Available completed NCT02991898
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies No drug interventions treatment 2 terminated NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor treatment 2 completed NCT00384228
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL treatment 1 / 2 completed NCT01326728
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation No drug interventions Not Available Not Available terminated NCT03674411
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy treatment 2 active_not_recruiting NCT00697671
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies treatment 1 completed NCT03625388
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia treatment 2 completed NCT04904588
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide treatment 2 recruiting NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell No drug interventions treatment 1 / 2 completed NCT02581007
Reduced Intensity Conditioning Transplant Using Haploidentical Donors treatment 2 completed NCT01036009
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies No drug interventions treatment 2 completed NCT00415909
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients treatment 2 terminated NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention supportive_care 3 completed NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) prevention 2 completed NCT00285259
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) No drug interventions treatment 2 completed NCT02639559
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies treatment 2 completed NCT02829775
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies treatment 2 / 3 completed NCT01020175
Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation No drug interventions treatment 3 completed NCT00413270
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant Not Available Not Available no_longer_available NCT03216070
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia treatment 4 unknown_status NCT00569842
Investigation of the Cylex® ImmuKnow® Assay No drug interventions Not Available Not Available completed NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases treatment Not Available recruiting NCT00513318
Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies No drug interventions Not Available Not Available terminated NCT01294618
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia treatment 2 completed NCT00739141
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. treatment 2 completed NCT01452334
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy No drug interventions treatment 1 withdrawn NCT00042016
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) treatment 2 completed NCT00089596
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers No drug interventions treatment 1 / 2 completed NCT00967525
Intraosseous Infusion of Unrelated Cord Blood Grafts No drug interventions treatment Not Available terminated NCT01075425
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome treatment 1 completed NCT02501330
Safety And Efficacy Of Bosutinib Not Available Not Available completed NCT00081926
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia treatment 4 completed NCT01901666
Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission diagnostic 4 unknown_status NCT00334074
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS treatment 2 completed NCT01690520
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes treatment 2 completed NCT00660920
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies treatment 1 completed NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine treatment 1 active_not_recruiting NCT01279473
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) treatment 1 / 2 completed NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant No drug interventions treatment 1 terminated NCT00412360
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) treatment 3 completed NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant treatment 2 completed NCT00333840
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia treatment 3 completed NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies treatment 2 completed NCT05434312
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients No drug interventions treatment 1 recruiting NCT06530810
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) treatment 1 not_yet_recruiting NCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies treatment 1 / 2 completed NCT00580281
Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors No drug interventions diagnostic Not Available completed NCT00539695
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD treatment 2 completed NCT02566395
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies treatment 3 completed NCT00816114
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial No drug interventions Not Available Not Available recruiting NCT01316250
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia treatment Not Available recruiting NCT02593123
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis treatment 2 completed NCT01368523
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial treatment 4 completed NCT00003838
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow treatment 2 completed